Navigation Links
$4 million NCI grant funds comparative effectiveness research at Southwest Oncology Group
Date:10/15/2009

ANN ARBOR, Mich. A $4 million National Cancer Institute (NCI) grant will help position the Southwest Oncology Group, one of the largest NCI-funded clinical trial cooperative groups, as a national leader in comparative effectiveness research on cancer.

The Grand Opportunities (GO) award supports the development of the Center for Comparative Effectiveness Research in Cancer Genomics, or CANCERGEN, under the direction of Scott Ramsey, M.D., Ph.D., of the Fred Hutchinson Cancer Research Center in Seattle. Researchers at the University of Washington, Cancer Research And Biostatistics (CRAB) in Seattle, and the Center for Medical Technology Policy in Baltimore will co-lead the effort.

CANCERGEN will create a comprehensive process to evaluate emerging cancer genomics technologies and identify those that are most promising. The University of Michigan-based Southwest Oncology Group, or SWOG, will use this process to help it select and launch those clinical trials that will have the greatest impact.

"CANCERGEN will provide us objective tools to determine which proposed trials are most likely to have a significant clinical benefit for patients," says SWOG Group Chair Laurence H. Baker, D.O., "and we will commit to doing only those trials that meet this new standard."

Comparative effectiveness research, or CER, has gained national attention and a surge of federal stimulus funding because it is seen as a means of slowing the growth of runaway health care costs in the U.S. by moving the system away from expensive but marginally effective treatments.

A recent Institute of Medicine report on comparative effectiveness research has influenced many of the health care reform proposals now wending their way through the U.S Congress.

"Realizing [CANCERGEN's] vision will go a long way to help achieve the health care reform goal of making cancer treatment more effective and less expensive," says the Hutchinson's Ramsey.

The first SWOG clinical trial proposal slated for support under CANCERGEN will assess whether a genetic test known as the Oncotype DX assay can predict which patients with node-positive breast cancer breast cancer that has spread to their lymph nodes will benefit from chemotherapy and which patients will not.

The study was one of five comparative effectiveness trial proposals NCI Director John Niederhuber, M.D., submitted to the National Institutes of Health in January of 2009 as candidates for federal stimulus funding. It is expected to serve as a model for future comparative effectiveness studies of cancer genomics technologies.

More about CANCERGEN's first trial:

The Oncotype DX genetic assay is now routinely used to test the tumors of patients whose breast cancer has not spread to their lymph nodes node-negative breast cancer. By measuring the expression or activity level of 21 specific genes within the tumor, the assay helps oncologists decide on treatment options by predicting whether a patient is likely to benefit from a course of chemotherapy.

SWOG 0930 is a proposed nationwide phase 3 clinical trial to determine whether this genetic test has the same predictive value for patients with node-positive breast cancer -- those whose cancer has spread to their lymph nodes. In 2008 about one-third of the 184,000 women diagnosed with breast cancer in the U.S. had cancer that had spread to their lymph nodes at the time of diagnosis.

The genetic assay is expensive, costing about $3,500 per test. Yet the chemotherapy treatment now routinely given to node-positive breast cancer patients costs on the order of $50,000 per year. If the Oncotype DX assay does prove to predict which node-positive patients will see no benefit from this chemotherapy, it could spare thousands of women the grisly effects of a course of chemotherapy that will not help lengthen their life, while at the same time saving hundreds of millions of dollars in health care costs each year.


'/>"/>

Contact: Frank DeSanto
fdesanto@umich.edu
734-998-0114
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Case Western Reserve University receives $20.5 million
2. NIH awards more than $54 Million to Kaiser Permanente to conduct health research
3. National pain research center will bring hope to millions
4. Medicare Cutbacks Threaten to Put Cardiac Care Out of Reach for Millions of Rural Americans
5. Medicare Cutbacks Threaten to Put Cardiac Care Out of Reach for Millions of Rural Americans
6. Hutchinson Center scientists net $16.7 million for stem cell research
7. Cord Blood America Announces Debt Reduction Tally: $8.7 Million in 2009; $3.7 Million in Third Quarter
8. The 24th Annual Great Sports Legends Dinner Raises More Than $6.3 Million for the Buoniconti Fund to Cure Paralysis
9. Wayne State University to Lead $6.25 Million NIH Research Program on One of the Most Common Inherited Neurological Disorders: Charcot-Marie-Tooth Disease
10. Glide Health Corporation and Integrated Medical Professionals Announce Partnership to Deploy the Glide Mobile Health Platform to Over One Million Patients and Over 100 Physicians in 50 Locations
11. Federal stimulus funding channels more than $40 million to Fred Hutchinson Cancer Research Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
(Date:10/12/2017)... BALTIMORE (PRWEB) , ... October 12, 2017 , ... ... average of $3,296 in property taxes a year. In some states—like New York, ... higher. , By contrast, many overseas retirement havens have extremely low property-tax rates, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... at the University of California Berkeley, and other leading institutions in announcing the ... power of institutions to change the way animals are raised for food. , ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... biologics manufacturer, has expanded its executive staff with the addition of industry sales ... this role, Slott will develop the national distribution and sales network, direct the ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) ... developed an innovative way to use nonlinear optical imaging ... of new drugs. ... Conference will show how researchers from BioPharmX and the ... School used a suite of imaging techniques in what ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
Breaking Medicine Technology: